Using prior knowledge of the importance of the coronavirus spike proteins in pathogenesis and immunity as well as the SARS-CoV-2 genetic sequence, researchers at the National Institute of Allergy and Infectious Disease and Moderna (Cambridge, MA) rapidly developed an mRNA vaccine against SARS-CoV-2. This lipid nanoparticle-encapsulated mRNA vaccine candidate (mRNA-1273) contains a portion of the spike glycoprotein subunit S2 (S-2P)….
